Scholarlink

Background <p>Anesthesia option is critical for Percutaneous vertebroplasty (PVP) procedure in terms of its analgesic effect, sedation, adverse reactions and patient satisfaction. Oxycodone and sufentanil are commonly used as analgesic agents for surgeries in clinic. The comparison of clinical effect between oxycodone and sufentanil for pain management in PVP has not been elucidated.</p> Questions/purposes <p>In this retrospective study, we investigated the clinical effect of oxycodone injection for pain management in spinal percutaneous vertebroplasty (PVP) surgery in terms of the analgesic effect, sedation, adverse reactions and patient satisfaction.</p> Methods <p>A total of 100 patients who had previously undergone spinal PVP surgery were selected for a retrospective study from December 2022 to June 2024 including the oxycodone group (50 cases) and the sufentanil group (50 cases). The sufentanil group received 1&#xa0;mg/kg propofol + 0.15ug/kg sufentanil as anesthetic, while the oxycodone group received 0.1&#xa0;mg/kg oxycodone + 1&#xa0;mg/kg propofol. The analgesic effects and safety of both groups were compared.</p> Results <p>The intraoperative additional dose of propofol, MOAA/S score, and number of body movements of the oxycodone group were lower than the sufentanil group (<i>p</i> &lt; 0.05); on postoperative day 1, the changes in SBP, DBP, HR, and SpO2 in the oxycodone group were lower than the sufentanil group (<i>p</i> &lt; 0.05); 1&#xa0;day and 3days after surgery, the oxycodone group had significantly lower VAS scores (<i>p</i> &lt; 0.001); The oxycodone group showed significantly lower postoperative pain intensity compared with the sufentanil group. On postoperative day 1, mean VAS scores were 2.76 ± 0.82 in the oxycodone group and 4.30 ± 0.73 in the sufentanil group (<i>P</i> &lt; 0.05). On postoperative day 3, VAS scores were 1.26 ± 0.44 vs. 2.04 ± 0.70, respectively (<i>P</i> &lt; 0.05).</p> Conclusion <p>Using oxycodone hydrochloride for intraoperative pain management in patients undergoing percutaneous vertebroplasty can effectively alleviate pain, maintain hemodynamic stability, improve intraoperative and postoperative analgesic effects, and has good safety, making it worth promoting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oxycodone versus sufentanil on pain management for spinal PVP surgery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月1日

查看全文
  • Jing Zhao,
  • Shanshan Yu,
  • Jingfei Deng,
  • Enliang Li,
  • Xiaoli Han,
  • Yujie Chen

摘要

Background

Anesthesia option is critical for Percutaneous vertebroplasty (PVP) procedure in terms of its analgesic effect, sedation, adverse reactions and patient satisfaction. Oxycodone and sufentanil are commonly used as analgesic agents for surgeries in clinic. The comparison of clinical effect between oxycodone and sufentanil for pain management in PVP has not been elucidated.

Questions/purposes

In this retrospective study, we investigated the clinical effect of oxycodone injection for pain management in spinal percutaneous vertebroplasty (PVP) surgery in terms of the analgesic effect, sedation, adverse reactions and patient satisfaction.

Methods

A total of 100 patients who had previously undergone spinal PVP surgery were selected for a retrospective study from December 2022 to June 2024 including the oxycodone group (50 cases) and the sufentanil group (50 cases). The sufentanil group received 1 mg/kg propofol + 0.15ug/kg sufentanil as anesthetic, while the oxycodone group received 0.1 mg/kg oxycodone + 1 mg/kg propofol. The analgesic effects and safety of both groups were compared.

Results

The intraoperative additional dose of propofol, MOAA/S score, and number of body movements of the oxycodone group were lower than the sufentanil group (p < 0.05); on postoperative day 1, the changes in SBP, DBP, HR, and SpO2 in the oxycodone group were lower than the sufentanil group (p < 0.05); 1 day and 3days after surgery, the oxycodone group had significantly lower VAS scores (p < 0.001); The oxycodone group showed significantly lower postoperative pain intensity compared with the sufentanil group. On postoperative day 1, mean VAS scores were 2.76 ± 0.82 in the oxycodone group and 4.30 ± 0.73 in the sufentanil group (P < 0.05). On postoperative day 3, VAS scores were 1.26 ± 0.44 vs. 2.04 ± 0.70, respectively (P < 0.05).

Conclusion

Using oxycodone hydrochloride for intraoperative pain management in patients undergoing percutaneous vertebroplasty can effectively alleviate pain, maintain hemodynamic stability, improve intraoperative and postoperative analgesic effects, and has good safety, making it worth promoting.